

In re Application of: Yoram Reiter et al  
 Serial No.: 10/510,229  
 Filed: October 13, 2004  
 Office Action Mailing Date: January 24, 2007

Examiner: Lucas, Zachariah  
 Group Art Unit: 1648  
 Attorney Docket: 28429

**In the Claims:**

Claims 1-140 (Canceled).

141. (Currently amended) A method of killing or damaging a target human cell expressing or displaying ~~an antigen-presenting portion of a~~ complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen, the method comprising exposing the target cell to a composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding the complex, antigen-presenting portion of the complex, wherein the antibody does not bind the human antigen-presenting molecule in an absence of the antigen derived from the pathogen, and wherein the antibody does not bind the antigen derived from the pathogen in an absence of the human antigen-presenting molecule, thereby killing or damaging a the target human cell expressing or displaying ~~an antigen-presenting portion of a~~ the complex composed of a the human antigen-presenting molecule and ~~an~~ the antigen derived from ~~a~~ the pathogen.

142. (Original) The method of claim 141, wherein said composition-of-matter further comprises a toxin attached to said antibody or antibody fragment.

143. (Original) The method of claim 142, wherein said toxin is *Pseudomonas* exotoxin A or a portion thereof.

144. (Original) The method of claim 141, further comprising the step of obtaining the target cell from an individual.

In re Application of: Yoram Reiter et al  
 Serial No.: 10/510,229  
 Filed: October 13, 2004  
 Office Action Mailing Date: January 24, 2007

Examiner: Lucas, Zachariah  
 Group Art Unit: 1648  
 Attorney Docket: 28429

145. (Original) The method of claim 141, wherein said exposing the cell to said composition-of-matter is effected by administering said composition-of-matter to an individual.

146. (Original) The method of claim 141, wherein the target cell is infected with the pathogen.

147. (Original) The method of claim 141, wherein the target cell is a T-lymphocyte or an antigen presenting cell.

148. (Original) The method of claim 141, wherein said antigen presenting cell is a B cell or a dendritic cell.

149. (Original) The method of claim 141, wherein said antibody fragment is a single chain Fv.

150. (Currently Amended) The method of claim 141, wherein said antigen-binding region includes ~~an amino acid sequences selected from the group consisting of~~ as set forth in SEQ ID NOs: 14-, 15, 16, 17, 18 and 19.

151. (Currently Amended) The method of claim 141, wherein said binding of said antibody or antibody fragment to said ~~antigen-presenting portion of said~~ complex is characterized by an affinity having a dissociation constant selected from the range consisting of  $1 \times 10^{-2}$  molar to  $5 \times 10^{-16}$  molar.

152. (Original) The method of claim 141, wherein said human antigen-presenting molecule is a major histocompatibility complex molecule.

In re Application of: Yoram Reiter et al  
Serial No.: 10/510,229  
Filed: October 13, 2004  
Office Action Mailing Date: January 24, 2007

Examiner: Lucas, Zachariah  
Group Art Unit: 1648  
Attorney Docket: 28429

153. (Original) The method of claim 152, wherein said major histocompatibility complex molecule is a major histocompatibility complex class I molecule.

154. (Original) The method of claim 153, wherein said major histocompatibility complex class I molecule is an HLA-A2 molecule.

155. (Original) The method of claim 141, wherein said pathogen is a viral pathogen.

156. (Original) The method of claim 155, wherein said viral pathogen is a retrovirus.

157. (Original) The method of claim 156, wherein said retrovirus is human T lymphotropic virus-1.

158. (Original) The method of claim 141, wherein said antigen derived from a pathogen is restricted by the antigen-presenting molecule.

159. (Original) The method of claim 141, wherein said antigen derived from a pathogen is a polypeptide.

160. (Original) The method of claim 159, wherein said polypeptide is a segment of a Tax protein, or a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3.

161-195. (Canceled)

In re Application of: Yoram Reiter et al  
Serial No.: 10/510,229  
Filed: October 13, 2004  
Office Action Mailing Date: January 24, 2007

Examiner: Lucas, Zachariah  
Group Art Unit: 1648  
Attorney Docket: 28429

196. (New) The method of claim 141, wherein said antibody or antibody fragment comprises an antibody constant region.

197. (New) The method of claim 161, wherein said constant region is capable of inducing antibody-dependent cell mediated cytotoxicity (ADCC).

198. (New) The method of claim 161, wherein said constant region is capable of initiating a complement cascade.

199. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:20, 21, 22, 23, 24 and 25.

200. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:26, 27, 28, 29, 30 and 31.

201. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:32, 33, 34, 35, 36 and 37.

202. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:38, 39, 40, 41, 42 and 43.

203. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:44, 45, 46, 47, 48 and 49.

204. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:50, 51, 52, 53, 54 and 55.

In re Application of: Yoram Reiter et al  
Serial No.: 10/510,229  
Filed: October 13, 2004  
Office Action Mailing Date: January 24, 2007

Examiner: Lucas, Zachariah  
Group Art Unit: 1648  
Attorney Docket: 28429

205. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:56, 57, 58, 59, 60 and 61.

206. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:62, 63, 64, 65, 66 and 67.

207. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:68, 69, 70, 71, 72 and 73.

208. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:74, 75, 76, 77, 78 and 79.

209. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:80, 81, 82, 83, 84 and 85.

210. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:86, 87, 88, 89, 90 and 91.

211. (New) The method of claim 141, wherein said antigen-binding region includes amino acid sequences as set forth in SEQ ID NOs:92, 93, 94, 95, 96 and 97.